SCHEMBL14067142

SCHEMBL14067142

CNc1nc2ccccc2nc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.58
PGK1 P00558 1/20 0.56
KDM4E B2RXH2 6/20 0.56
L3MBTL1 Q9Y468 5/20 0.56
NPSR1 Q6W5P4 2/20 0.56
RXFP1 Q9HBX9 8/20 0.51
ALDH1A1 P00352 4/20 0.51
POLB P06746 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.46
HTT P42858 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
PKM P14618 1/20 0.45
HPGD P15428 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29340312 0.79 PGK1 (0.57) TDP1PGK1KDM4EL3MBTL1NPSR1
SCHEMBL29340314 0.79 PGK1 (0.57) TDP1PGK1KDM4EL3MBTL1NPSR1
SCHEMBL462643 0.78 TDP1 (0.58) TDP1KDM4EL3MBTL1NPSR1RXFP1
SCHEMBL17014813 0.78 KDM4E (0.70) TDP1PGK1KDM4EL3MBTL1NPSR1
SCHEMBL6993440 0.76 MAPT (0.51) TDP1KDM4EL3MBTL1ALDH1A1POLB
SCHEMBL116696 0.75 TDP1 (1.00) TDP1KDM4EL3MBTL1NPSR1RXFP1
SCHEMBL29451077 0.75 TDP1 (1.00) TDP1KDM4EL3MBTL1NPSR1RXFP1
SCHEMBL18323559 0.75 TDP1 (0.54) TDP1KDM4EL3MBTL1NPSR1RXFP1
SCHEMBL2302871 0.75 RXFP1 (0.66) TDP1KDM4EL3MBTL1NPSR1RXFP1
SCHEMBL6217678 0.75 KDM4E (0.81) TDP1PGK1KDM4EL3MBTL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4400505-A1 PEPTIDE-UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOF Bivision Pharmaceuticals, Inc (CN) 2024-07-17 EP disclosed
CN-107074896-B Electroluminescent imidazoquinoxaline carbene metal complexes UDC 爱尔兰有限责任公司 2021-04-13 CN disclosed
US-10784448-B2 Electroluminescent imidazo-quinoxaline carbene metal complexes UDC IRELAND LIMITED (IE) 2020-09-22 US disclosed
US-10428075-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2019-10-01 US disclosed
EP-3466957-A1 OLED COMPRISING AN ELECTROLUMINESCENT IMIDAZO-QUINOXALINE CARBENE METAL COMPLEXES UDC Ireland Limited (IE) 2019-04-10 EP disclosed
EP-3186264-B1 ELECTROLUMINESCENT IMIDAZO-QUINOXALINE CARBENE METAL COMPLEXES UDC IRELAND LTD (IE) 2018-11-28 EP disclosed
US-20180223184-A1 ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME ROHM & HAAS ELECT MATERIALS KOREA LTD (KR) 2018-08-09 US disclosed
US-20170237020-A1 Electroluminescent Imidazo-Quinoxaline Carbene Metal Complexes BASF SE (DE) 2017-08-17 US disclosed
EP-3186264-A1 ELECTROLUMINESCENT IMIDAZO-QUINOXALINE CARBENE METAL COMPLEXES UDC Ireland Limited (IE) 2017-07-05 EP disclosed
EP-3167887-A1 ARYL AMINE SUBSTITUTED QUINOXALINE USED AS ANTICANCER DRUGS Chen, Kuenfeng (TW) 2017-05-17 EP disclosed
WO-2016020516-A1 ELECTROLUMINESCENT IMIDAZO-QUINOXALINE CARBENE METAL COMPLEXES BASF SE (DE) 2016-02-11 WO disclosed
EP-1325910-B1 ALIPHATIC NITROGENOUS FIVE-MEMBERED RING COMPOUNDS MITSUBISHI TANABE PHARMA CORP (JP) 2008-09-17 EP disclosed
US-7160877-B2 Aliphatic nitrogen-containing 5-membered ring compound TANABE SEIYAKU CO., LTD. (JP) 2007-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428075-B2 Coelenterazine analogues GLB1, SI, TCF7L2 TDP1 3852/4885PGK1 3305/4885KDM4E 3302/4885
US-10784448-B2 Electroluminescent imidazo-quinoxaline carbene metal complexes OCIAD1, OCIAD2, OXER1 TDP1 4129/4885PGK1 2888/4885KDM4E 3834/4885
US-20170237020-A1 Electroluminescent Imidazo-Quinoxaline Carbene Metal Complexes OCIAD1, OCIAD2, OXER1 TDP1 4129/4885PGK1 2888/4885KDM4E 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.